Abstract
Biomarkers as a Diagnostic Tool in Cancer: A Boon or a Bane?
Priyanka Varma*
Corresponding Author: Priyanka Varma, MD, MSc, CCRP, Preferred Medicine Inc., Burlingame, California, USA.
Revised: November 11, 2021; Available Online: November 11, 2021
Citation: Varma P. (2021) Biomarkers as a Diagnostic Tool in Cancer: A Boon or a Bane?BioMed Res J, 5(S2): 06.
Copyrights: ©2021 Varma P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 69

    Views & Citations
Cancer Screening is a hotly debated and extensively researched topic. There are several screening modalities currently in application as well as being researched with the sole aim to detect cancer early and eventually eradicate it. The development of Next Generation Sequencing in genomic analysis and identifying biomarkers has garnered an exponentially growing interest amongst cancer researchers to precisely diagnose the presence of cancer at an early stage, thereby reducing the morbidity and mortality and potentially assisting with the prognostic and predictive profiling. The diagnostic and clinical efficacy of these biomarkers are potentially instrumental in helping improve the clinical outcome of cancer and should be researched with this goal in mind.

Keywords: Biomarker, Diagnostic, Cancer, Next generation sequencing, Detect early